The firm's molecular revenues rose 72 percent during the fourth quarter and 75 percent during full-year 2016.
Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The FDA go-ahead marks Quidel's fourth MDx test to receive 510(k) clearance for the Solana platform.
The test runs on the company's Solana instrument, which can process up to 12 patient samples in a 45-minute run.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.